|
Forecast
Period
|
2026-2030
|
|
Market
Size (2024)
|
USD
6.41 Billion
|
|
CAGR
(2025-2030)
|
6.60%
|
|
Fastest
Growing Segment
|
Lab
Testing
|
|
Largest
Market
|
China
|
|
Market
Size (2030)
|
USD 9.30 Billion
|
Market Overview
Asia
Pacific Cancer Diagnostics Market was valued at USD 6.41 Billion in 2024 and is
expected to reach USD 9.30 Billion by 2030 with a CAGR of 6.60%. As the region
faces a growing burden of non-communicable diseases, cancer has emerged as one
of the leading causes of mortality, prompting governments, healthcare providers,
and private players to strengthen diagnostic capabilities and expand access to
screening programs. One of the primary drivers of market expansion is the
increasing adoption of advanced molecular diagnostics, such as polymerase chain
reaction (PCR), next-generation sequencing (NGS), and liquid biopsy.
These
technologies are transforming the landscape of cancer detection and management
by enabling early diagnosis, precise tumor profiling, and personalized
treatment strategies. Despite the positive outlook, the market faces challenges
such as unequal access to diagnostics in rural and underserved areas, high
costs associated with advanced technologies, and fragmented regulatory
frameworks. Addressing these issues will be crucial to ensuring equitable
access and sustaining market growth.
Key Market Drivers
Growth in Healthcare Industry
Asia’s
healthcare market is projected to reach USD 5 trillion by 2030, accounting for
40% of the global healthcare sector’s growth. The ongoing expansion of the healthcare
industry across the Asia Pacific is a major force propelling growth in the
region's cancer diagnostics market. Governments and private stakeholders have
increased healthcare expenditure and upgraded infrastructure, enabling
hospitals and diagnostic centers to adopt advanced testing platforms. These
investments facilitate broader deployment of cancer screening and diagnostic
services nationwide.
An
aging population and higher incidence of cancer in countries like China, India,
Japan, and Australia have amplified the demand for early and accurate detection
methods. In 2020, Asia recorded a cancer incidence rate of 169.1 per 100,000
individuals, representing 49.3% of the global cancer burden. The most prevalent
cancer types were lung cancer (13.8%), breast cancer (10.8%), and colorectal
cancer (10.6%). The heightened disease burden has put pressure on
healthcare systems to enhance diagnostic capacity and enable timely
intervention. As a result, providers are increasingly integrating technologies
such as in vitro diagnostics, molecular testing, and liquid biopsies into
routine clinical practice.
Surge in Technological
Advancements
The
Asia Pacific cancer diagnostics market is undergoing significant growth,
largely driven by a surge in technological advancements that are transforming
the landscape of early detection, disease monitoring, and personalized
oncology. Notable, recent advancements in radiotherapy technology are poised
to significantly enhance cancer treatment outcomes in India. Innovations such
as Intensity-Modulated Radiotherapy (IMRT) and Image-Guided Radiotherapy (IGRT)
have transformed the therapeutic landscape by enabling the precise delivery of
higher radiation doses directly to tumors while minimizing exposure to
surrounding healthy tissue. As the burden of cancer continues to rise
across the region, innovations in diagnostic technologies are enabling faster,
more accurate, and less invasive detection methods, thereby improving clinical
outcomes and expanding access to quality cancer care.
One
of the most impactful technological developments has been the advancement of
molecular diagnostics, particularly next-generation sequencing (NGS), which
allows for comprehensive genomic profiling of tumors. This technology has
revolutionized precision oncology by enabling clinicians to identify specific
genetic mutations and tailor treatment strategies accordingly. The growing
availability of NGS platforms in countries such as China, Japan, and South
Korea has significantly improved the accuracy of cancer diagnosis and
strengthened the shift toward personalized medicine.
Download Free Sample Report
Key Market Challenges
High Cost of Advanced
Diagnostics
The
high cost of advanced diagnostics poses a significant challenge to the growth
and accessibility of the cancer diagnostics market in the Asia Pacific region.
While technologies such as next-generation sequencing (NGS), liquid biopsy, and
molecular imaging offer superior accuracy and enable personalized cancer
treatment, their widespread adoption is hindered by the substantial financial
burden they impose on healthcare systems, providers, and patients particularly
in low- and middle-income countries.
Advanced
diagnostic procedures often require sophisticated equipment, specialized
laboratory infrastructure, and highly trained personnel, all of which
contribute to increased operational expenses. The cost of acquiring, maintaining,
and operating these systems can be prohibitive for many public healthcare
facilities, especially in developing economies across Southeast Asia, South
Asia, and parts of the Pacific. This financial barrier limits the availability
of state-of-the-art diagnostic services to a small segment of the population,
primarily those in urban centers or those who can afford private healthcare.
Key Market Trends
Expansion of Multi-Omics and
Integrated Biomarker Platforms
In
the Asia Pacific region, cancer diagnostics is undergoing a profound shift,
driven by the rapid integration of multi-omics and biomarker platforms. The
swift adoption of artificial intelligence—particularly deep learning and
machine learning is transforming biomarker development by uncovering insights
from complex data patterns and accelerating the advancement of technologies
that support the delivery of precise and effective therapies. This trend
reflects a growing recognition that traditional single-marker tests are
insufficient to capture the complex molecular signatures of cancer. Today's
diagnostic landscape is moving toward comprehensive approaches that combine
genomic, proteomic, metabolomic, and epigenomic data to deliver more precise
detection and tailored treatment strategies.
Multi-omics
platforms enable deep profiling of tumors at multiple molecular levels.
Next-generation sequencing (NGS) and real-time PCR tools analyze genetic
mutations and gene expression patterns, while proteomic and metabolomic assays
add layers of protein and small-molecule information. By integrating these
diverse data types, clinicians can better stratify patients, track disease
progression, and predict therapeutic response with higher confidence. Such
integrative diagnostics are gaining traction in major Asia Pacific countries China,
India, Japan, and South Korea under government strategies like China's Healthy
China 2030 program and India's Genome India initiative, both of which support
biomarker innovation and precision oncology efforts.
Segmental Insights
Type Insights
Based
on Type, Lab Testing have emerged as the fastest growing segment in the Asia
Pacific Cancer Diagnostics Market in 2024. One of the primary factors driving
the rapid expansion of lab testing is the rising adoption of advanced molecular
diagnostics, such as PCR (polymerase chain reaction), next-generation
sequencing (NGS), and fluorescence in situ hybridization (FISH). These
techniques allow for precise identification of genetic mutations, tumor
markers, and other molecular signatures associated with various cancer types.
As precision oncology gains momentum in countries like China, India, Japan, and
South Korea, demand for such sophisticated lab-based tests has grown
exponentially.
Application Insights
Based
on Application, Lung Cancer have emerged as the fastest growing segment in the Asia
Pacific Cancer Diagnostics Market during the forecast period. This is due to
its rising incidence, high mortality rate, and growing demand for early and
accurate detection methods. The region has witnessed a significant increase in
lung cancer cases, largely driven by high smoking rates, worsening air
pollution, and occupational exposure to harmful substances in rapidly
industrializing economies such as China, India, and Southeast Asian countries.
As lung cancer is often diagnosed at advanced stages, there is a critical need
for timely and precise diagnostic tools to improve patient outcomes.
Download Free Sample Report
Country Insights
Based
on Country, China have emerged as the dominating country in the Asia Pacific
Cancer Diagnostics Market in 2024. This is due to a combination of demographic
scale, robust government support, and rapid technological advancement in
healthcare. With the world’s largest population and one of the highest cancer
incidence rates in the region, China represents a substantial and growing
demand base for early detection and precision oncology solutions. The Chinese
government has prioritized cancer care within its national health agenda,
leading to the implementation of large-scale cancer screening programs and
investments in diagnostic infrastructure across both urban and rural areas.
Recent Development
- In
May 2025, Metropolis Healthcare introduced the TruHealth Cancer Screen 360—an
advanced and comprehensive cancer screening panel designed to address the
escalating cancer burden in India. This launch marks a significant milestone in
the Indian diagnostics industry, positioning the company’s preventive oncology
portfolio as a pioneering solution. The TruHealth Cancer Screen 360 features
scientifically curated Male and Female Profiles, tailored to deliver early
diagnostic insights for clinicians and individuals alike. The initiative seeks
to broaden access to specialised cancer diagnostics while promoting greater
affordability and inclusivity in cancer screening services.
- In
April 2025, the Tata Memorial Centre (TMC) officially launched MenCan, a
dedicated initiative developed by the Urologic Oncology Disease Management
Group (URO DMG). This nonprofit, non-commercial program aims to address the
growing incidence of prostate, penile, and testicular cancers in India. As part
of its long-term strategy, MenCan is focused on ensuring sustainability and
nationwide scalability by expanding its services across all Tata Memorial
Centre locations in the country.
- In
April 2025, TGH Onco-Life Cancer Centre launched a mobile van equipped with an
integrated breast cancer screening unit, aimed at providing on-the-go
diagnostics. Supported by the Rotary Club of Talegaon, Dabhade, and donated by
POSCO India, the initiative is designed to facilitate early detection and
promote awareness among women in rural and semi-urban areas of Maharashtra. The
mobile unit will also extend its services to large corporate offices and
industrial sites, targeting underserved workers who often defer preventive
healthcare due to limited access or resources.
- In
January 2025, Agilus Diagnostics announced a groundbreaking advancement in
genomic testing, achieving an industry-leading turnaround time of just three
days for myeloid malignancy test results. The Myeloid Genomics Testing and
Precision Assay is engineered to deliver faster and more accurate insights into
cancer and myeloid disorders. This testing panel analyzes 79 genes, including
those associated with inherited risk factors, to identify critical genetic
alterations such as mutations and fusions. The results support personalized
treatment strategies for diseases including Acute Myeloid Leukemia (AML) and
Myeloproliferative Neoplasms (MPN). Each report undergoes expert pathologist
review and incorporates internationally recognized risk assessment frameworks
alongside tailored therapeutic recommendations.
Key Market Players
- Thermo Fisher
Scientific, Inc.
- GE
Healthcare
- Abbott
Laboratories, Inc.
- Becton,
Dickinson, and Company
- F.
Hoffmann-La Roche Ltd.
- Boehringer-Ingelheim
International GmbH
|
By
Type
|
By
Application
|
By
Country
|
- Lab
Testing
- Genetic
Testing
- Imaging
Testing
- Biomarkers
Testing
- In
Vitro Diagnostic Testing
- Biopsy
- Others
|
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Kidney Cancer
- Skin cancer
- Others
|
- China
- India
- Japan
- Australia
- South
Korea
- Rest
of Asia Pacific
|
Report Scope
In this report, the Asia Pacific Cancer Diagnostics
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Asia Pacific Cancer Diagnostics Market, By Type:
o Lab Testing
o Genetic Testing
o Imaging Testing
o Biomarkers Testing
o In Vitro Diagnostic Testing
o Biopsy
o Others
- Asia Pacific Cancer Diagnostics Market, By Application:
o Lung Cancer
o Breast Cancer
o Colorectal Cancer
o Prostate Cancer
o Kidney Cancer
o Skin cancer
o Others
- Asia Pacific Cancer Diagnostics Market, By Country:
o China
o India
o Japan
o Australia
o South Korea
o Rest of Asia Pacific
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Asia
Pacific Cancer Diagnostics Market.
Available Customizations:
Asia Pacific Cancer Diagnostics Market report with
the given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Asia Pacific Cancer
Diagnostics Market is an upcoming report to be released soon. If you wish an
early delivery of this report or want to confirm the date of release, please
contact us at [email protected]